Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.

Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.

A labeling arrangement for a multi-part container includes a sleeve-shaped cap element adapted to be coupled to and surround a closure of the container, the cap element having, relative to a longitudinal axis, first and second cap portions and a severing region. The labeling arrangement further includes a fixing label having adjacent first and second label portions. The first label portion is adapted to be attached to the second cap portion, and the second label portion is adapted to be attached to a container body of the container such that the fixation label couples the cap element to the container body, such that when the container with the labeling arrangement is opened, the cap element is separable in the severing region and at least a part of the first cap portion together with a part of the closure is removable from the second cap portion and the container body.

A device for discharging a flowable substance, in particular for applying a medical substance, a pharmaceutical substance, a food supplement or a cosmetics, includes_an activation mechanism and a body which has a discharge opening at a first end and forms a containing space in which a frangible capsule is disposed. The capsule has two ends each having a first and a second tip and at least one of the two tips can be snapped off by actuating the activation mechanism so that the flowable substance is discharged.

Methods, assays, compositions and kits for the ligation of short polynucleotides are presented herein. The short polynucleotides are optionally no more than 7 nucleotides in length, and can be as short as 3 or 4 nucleotides in length. The ligation is optionally performed by CV ligase.

A liquid medication dispenser is provided having a dispenser housing with a housing interior. A plurality of syringe openings may be provided in the dispenser housing. A housing lid may be carried by the dispenser housing. A plurality of medication container seats may be provided in the housing lid. A plurality of medication dispensing openings may be provided in the plurality of medication container seats, respectively. A face plate may be carried by the dispenser housing. A plurality of syringe barrel cavities may be provided in the face plate and disposed in aligned or registering relationship with respect to the plurality of syringe openings, respectively. The syringe barrel cavities may have different sizes. A plurality of medication distribution assemblies may establish fluid communication between the plurality of medication dispensing openings, respectively, and the plurality of syringe openings, respectively.

Described is a cyclic olefin-based copolymer has a constitutional unit (A) derived from an α-olefin having 2 to 20 carbon atoms, a constitutional unit (B) derived from a cyclic olefin without an aromatic ring, and a constitutional unit (C) derived from a cyclic olefin having an aromatic ring. Also described is a medical container containing a cyclic olefin-based copolymer having a constitutional unit (A) derived from an α-olefin having 2 to 20 carbon atoms, a constitutional unit (B) derived from a cyclic olefin without an aromatic ring, and a constitutional unit (C) derived from a cyclic olefin having an aromatic ring.

Caps for sealing assemblies for sealing glass containers and maintaining container closure integrity at −80° C. or less are disclosed. The caps include a cap skirt having an annular body and a crimp region. The crimp region is a crimpable metal. The annular body of the cap skirt has a coefficient of thermal expansion (CTE) greater than a CTE of a metal consisting of aluminum, a stiffness greater than or equal to 2 times a stiffness of the crimp region, or both. The greater CTE, stiffness, or both of the cap skirt increase the seal pressure and contact area between the stopper and glass container when cooled to −80° C. or less. The caps enable the sealing assemblies to maintain a helium leakage rate of the sealed glass container of less than or equal to 1.4×10.sup.−6 cm.sup.3/s at −80° C. or less.

A device for delivering a liquid specialty of the pharmaceutical or food supplement type comprises a gelatin reservoir and a cap hermetically closing the reservoir. The device further comprises a tab arranged on the opposite side of the cap with respect to the reservoir, the tab being filled with gelatin.

Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness T.sub.i that is less than or equal to 0.85*s.sub.1, wherein s.sub.1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.